Curative Ventures is a capital and talent partner to category-defining biotech companies that are developing new therapies to dramatically improve patient outcomes.
Recent Investments
Press Releases
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil [...]
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. [...]
Vertex Enters Duchenne Therapy Market with $1B Acquisition of Exonics
Move over, Sarepta Therapeutics, Solid Biosciences, PTC Therapeutics and [...]
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline Acquisition [...]
Peloton Therapeutics Secures $150 Million in Series E Financing
- Proceeds to advance oral HIF-2α inhibitor, PT2977, into [...]
TCR2 Therapeutics Prices IPO Of 5 Mln Shares At $15.00/shr
(RTTNews) Feb 13, 2019 - TCR2 Therapeutics Inc. (TCRR) said [...]
Contact Us
Curative Ventures
info@curativeventures.com
Address
3963 Maple Avenue, Suite 350
Dallas, TX 75219